610 related articles for article (PubMed ID: 28722012)
1. Type III CRISPR-Cas systems produce cyclic oligoadenylate second messengers.
Niewoehner O; Garcia-Doval C; Rostøl JT; Berk C; Schwede F; Bigler L; Hall J; Marraffini LA; Jinek M
Nature; 2017 Aug; 548(7669):543-548. PubMed ID: 28722012
[TBL] [Abstract][Full Text] [Related]
2. The ribonuclease activity of Csm6 is required for anti-plasmid immunity by Type III-A CRISPR-Cas systems.
Foster K; Kalter J; Woodside W; Terns RM; Terns MP
RNA Biol; 2019 Apr; 16(4):449-460. PubMed ID: 29995577
[TBL] [Abstract][Full Text] [Related]
3. Activation and self-inactivation mechanisms of the cyclic oligoadenylate-dependent CRISPR ribonuclease Csm6.
Garcia-Doval C; Schwede F; Berk C; Rostøl JT; Niewoehner O; Tejero O; Hall J; Marraffini LA; Jinek M
Nat Commun; 2020 Mar; 11(1):1596. PubMed ID: 32221291
[TBL] [Abstract][Full Text] [Related]
4. A Type III CRISPR Ancillary Ribonuclease Degrades Its Cyclic Oligoadenylate Activator.
Athukoralage JS; Graham S; Grüschow S; Rouillon C; White MF
J Mol Biol; 2019 Jul; 431(15):2894-2899. PubMed ID: 31071326
[TBL] [Abstract][Full Text] [Related]
5. Activation of Csm6 ribonuclease by cyclic nucleotide binding: in an emergency, twist to open.
McQuarrie S; Athukoralage JS; McMahon SA; Graham S; Ackermann K; Bode BE; White MF; Gloster TM
Nucleic Acids Res; 2023 Oct; 51(19):10590-10605. PubMed ID: 37747760
[TBL] [Abstract][Full Text] [Related]
6. Regulation of cyclic oligoadenylate synthesis by the
Nasef M; Muffly MC; Beckman AB; Rowe SJ; Walker FC; Hatoum-Aslan A; Dunkle JA
RNA; 2019 Aug; 25(8):948-962. PubMed ID: 31076459
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-Cas III-A Csm6 CARF Domain Is a Ring Nuclease Triggering Stepwise cA
Jia N; Jones R; Yang G; Ouerfelli O; Patel DJ
Mol Cell; 2019 Sep; 75(5):944-956.e6. PubMed ID: 31326273
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for the endoribonuclease activity of the type III-A CRISPR-associated protein Csm6.
Niewoehner O; Jinek M
RNA; 2016 Mar; 22(3):318-29. PubMed ID: 26763118
[TBL] [Abstract][Full Text] [Related]
9. A Type III-B Cmr effector complex catalyzes the synthesis of cyclic oligoadenylate second messengers by cooperative substrate binding.
Han W; Stella S; Zhang Y; Guo T; Sulek K; Peng-Lundgren L; Montoya G; She Q
Nucleic Acids Res; 2018 Nov; 46(19):10319-10330. PubMed ID: 30239876
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanism of allosteric activation of the CRISPR ribonuclease Csm6 by cyclic tetra-adenylate.
Du L; Zhu Q; Lin Z
EMBO J; 2024 Jan; 43(2):304-315. PubMed ID: 38177499
[TBL] [Abstract][Full Text] [Related]
11. Csx3 is a cyclic oligonucleotide phosphodiesterase associated with type III CRISPR-Cas that degrades the second messenger cA
Brown S; Gauvin CC; Charbonneau AA; Burman N; Lawrence CM
J Biol Chem; 2020 Oct; 295(44):14963-14972. PubMed ID: 32826317
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the cyclic oligoadenylate signaling pathway of type III CRISPR systems.
Rouillon C; Athukoralage JS; Graham S; Grüschow S; White MF
Methods Enzymol; 2019; 616():191-218. PubMed ID: 30691643
[TBL] [Abstract][Full Text] [Related]
13. Tetramerisation of the CRISPR ring nuclease Crn3/Csx3 facilitates cyclic oligoadenylate cleavage.
Athukoralage JS; McQuarrie S; Grüschow S; Graham S; Gloster TM; White MF
Elife; 2020 Jun; 9():. PubMed ID: 32597755
[TBL] [Abstract][Full Text] [Related]
14. Type III-A CRISPR-associated protein Csm6 degrades cyclic hexa-adenylate activator using both CARF and HEPN domains.
Smalakyte D; Kazlauskiene M; F Havelund J; Rukšėnaitė A; Rimaite A; Tamulaitiene G; Færgeman NJ; Tamulaitis G; Siksnys V
Nucleic Acids Res; 2020 Sep; 48(16):9204-9217. PubMed ID: 32766806
[TBL] [Abstract][Full Text] [Related]
15. Enzymatic properties of CARF-domain proteins in
Ding J; Schuergers N; Baehre H; Wilde A
Front Microbiol; 2022; 13():1046388. PubMed ID: 36419420
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the RNA and DNA nuclease activities required for Pyrococcus furiosus Type III-B CRISPR-Cas immunity.
Foster K; Grüschow S; Bailey S; White MF; Terns MP
Nucleic Acids Res; 2020 May; 48(8):4418-4434. PubMed ID: 32198888
[TBL] [Abstract][Full Text] [Related]
17. A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems.
Kazlauskiene M; Kostiuk G; Venclovas Č; Tamulaitis G; Siksnys V
Science; 2017 Aug; 357(6351):605-609. PubMed ID: 28663439
[TBL] [Abstract][Full Text] [Related]
18. The CRISPR ancillary effector Can2 is a dual-specificity nuclease potentiating type III CRISPR defence.
Zhu W; McQuarrie S; Grüschow S; McMahon SA; Graham S; Gloster TM; White MF
Nucleic Acids Res; 2021 Mar; 49(5):2777-2789. PubMed ID: 33590098
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Oligonucleotide Signaling Mediated by CRISPR-Associated Polymerases Solves Two Puzzles but Leaves an Enigma.
Koonin EV; Makarova KS
ACS Chem Biol; 2018 Feb; 13(2):309-312. PubMed ID: 28937734
[TBL] [Abstract][Full Text] [Related]
20. If You'd Like to Stop a Type III CRISPR Ribonuclease, Then You Should Put a Ring (Nuclease) on It.
Mo CY; Marraffini LA
Mol Cell; 2018 Nov; 72(4):608-609. PubMed ID: 30444997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
